Thermo Fisher Scientific, a supplier of scientific instrumentation, completed the acquisition of The Binding Site, a specialty diagnostics provider, from Nordic Capital, a private equity investor, for $2.8bn. “This transaction perfectly aligns with our Mission and is an exciting addition to our existing specialty diagnostic offerings. With extensive expertise and a large and dedicated installed base in cancer diagnostics, The Binding Site will further enhance our specialty diagnostics portfolio. The Binding Site is extremely well-respected by researchers and clinicians alike for its pioneering diagnosis and monitoring solutions for multiple myeloma. We also know early diagnosis and well-informed treatment decisions for multiple myeloma can make a significant difference in patient outcomes. We are excited by the opportunity to enable further innovation in this area for the benefit of patients and look forward to welcoming The Binding Site team to Thermo Fisher," Marc N. Casper, Thermo Fisher Chairman, President and CEO.